Back to Search
Start Over
Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer
- Source :
- Journal of Thoracic Oncology. 11:1263-1272
- Publication Year :
- 2016
- Publisher :
- Elsevier BV, 2016.
-
Abstract
- Introduction Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells of myeloid origin whose expression is induced by, among others things, vascular endothelial growth factor. We have previously identified two monocytic and one granulocytic MDSC subpopulations associated with the clinical outcome in patients with non–small cell lung cancer (NSCLC). The aim of the present study was to evaluate the effect of chemotherapy on these MDSC subpopulations. Methods Circulating immune cells from 46 patients with unresectable NSCLC were analyzed by flow cytometry before the initiation of chemotherapy and after three cycles. Changes in the frequencies of the MDSC subpopulations were correlated with clinical outcome. Results Chemotherapy had no uniform effect on either the number or the functionality of monocytic and granulocytic MDSCs. However, three cycles of bevacizumab-containing regimens significantly reduced the percentage of the granulocytic-MDSCs compared with non–bevacizumab-based regimens ( p = 0.0086). At the time of evaluation of response, disease progression was associated with significantly higher levels of all three MDSC subpopulations compared with in patients with disease control. Ιn patients with disease progression after three cycles of chemotherapy, the percentage of CD15-positive monocytic MDSCs was significantly increased compared with baseline. Conclusions In the peripheral blood of patients with NSCLC, bevacizumab-based chemotherapy significantly reduced the levels of granulocytic MDSCs. An increase in the levels of CD15-positive monocytic MDSCs was associated with poor response to treatment and disease progression, providing evidence of their clinical relevance in patients with NSCLC.
- Subjects :
- Male
0301 basic medicine
Pulmonary and Respiratory Medicine
Lung Neoplasms
Myeloid
Bevacizumab
medicine.medical_treatment
Lipopolysaccharide Receptors
Lewis X Antigen
Flow cytometry
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Immune system
Carcinoma, Non-Small-Cell Lung
medicine
Humans
Lung cancer
Aged
Aged, 80 and over
Chemotherapy
medicine.diagnostic_test
business.industry
Myeloid-Derived Suppressor Cells
Middle Aged
medicine.disease
Vascular endothelial growth factor
030104 developmental biology
medicine.anatomical_structure
Oncology
chemistry
030220 oncology & carcinogenesis
Immunology
Myeloid-derived Suppressor Cell
Cancer research
Female
Reactive Oxygen Species
business
Immunosuppressive Agents
medicine.drug
Subjects
Details
- ISSN :
- 15560864
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of Thoracic Oncology
- Accession number :
- edsair.doi.dedup.....b2b5e60372ed382ca674abde8676fd5e